AIA Group Ltd Purchases 565 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

AIA Group Ltd grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.6% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 4,722 shares of the biopharmaceutical company’s stock after acquiring an additional 565 shares during the quarter. AIA Group Ltd’s holdings in Regeneron Pharmaceuticals were worth $4,147,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Annis Gardner Whiting Capital Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Sunbelt Securities Inc. purchased a new stake in Regeneron Pharmaceuticals during the 1st quarter valued at $25,000. Fortitude Family Office LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $31,000. Bruce G. Allen Investments LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at $40,000. Finally, Sutton Wealth Advisors Inc. raised its holdings in Regeneron Pharmaceuticals by 38.2% during the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 13 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Down 0.4 %

NASDAQ REGN traded down $3.27 during trading on Thursday, hitting $897.92. The company’s stock had a trading volume of 277,592 shares, compared to its average volume of 492,312. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market cap of $98.56 billion, a PE ratio of 25.93, a P/E/G ratio of 2.58 and a beta of 0.11. The business’s 50 day simple moving average is $955.19 and its 200-day simple moving average is $890.52. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, topping the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The company’s quarterly revenue was up .6% on a year-over-year basis. During the same quarter last year, the company earned $10.96 earnings per share. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 38.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on REGN shares. UBS Group increased their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday. Bank of America increased their price target on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a report on Friday, April 12th. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Sanford C. Bernstein began coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $976.41.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, EVP Marion Mccourt sold 358 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $967.50, for a total transaction of $346,365.00. Following the completion of the sale, the executive vice president now owns 13,431 shares of the company’s stock, valued at $12,994,492.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold 13,729 shares of company stock valued at $13,124,641 over the last quarter. 8.83% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.